ir.relmada.com ir.relmada.com

ir.relmada.com

Investor Relations :: Relmada Therapeutics, Inc. (RLMDD)

REL-1017 (dextromethadone, d-Methadone). Cash position on March 31, 2015. Headcount as of December 31, 2014. Common stock outstanding at May 15, 2015. Aug 17, 2015. Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist. Sign Up for E-Mail Alerts. Be the first to receive breaking news. Mar 31, 2015. Officers & Directors. Slide" data-cycle-swipe="true" data-cycle-timeout= 0. Douglas J. Beck. Michael D. Becker. Dr Mangano has ...

http://ir.relmada.com/

WEBSITE DETAILS
SEO
PAGES
SIMILAR SITES

TRAFFIC RANK FOR IR.RELMADA.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

April

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Wednesday

TRAFFIC BY CITY

CUSTOMER REVIEWS

Average Rating: 3.5 out of 5 with 8 reviews
5 star
1
4 star
4
3 star
2
2 star
0
1 star
1

Hey there! Start your review of ir.relmada.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

Desktop Preview Tablet Preview Mobile Preview

LOAD TIME

0.1 seconds

FAVICON PREVIEW

  • ir.relmada.com

    16x16

  • ir.relmada.com

    32x32

  • ir.relmada.com

    64x64

  • ir.relmada.com

    128x128

CONTACTS AT IR.RELMADA.COM

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

SCORE

6.2

PAGE TITLE
Investor Relations :: Relmada Therapeutics, Inc. (RLMDD) | ir.relmada.com Reviews
<META>
DESCRIPTION
REL-1017 (dextromethadone, d-Methadone). Cash position on March 31, 2015. Headcount as of December 31, 2014. Common stock outstanding at May 15, 2015. Aug 17, 2015. Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist. Sign Up for E-Mail Alerts. Be the first to receive breaking news. Mar 31, 2015. Officers & Directors. Slide data-cycle-swipe=true data-cycle-timeout= 0. Douglas J. Beck. Michael D. Becker. Dr Mangano has ...
<META>
KEYWORDS
1 about relmada
2 overview
3 management team
4 board of directors
5 scientific advisors
6 governance/compliance
7 product candidates
8 news and events
9 press releases
10 company news
CONTENT
Page content here
KEYWORDS ON
PAGE
about relmada,overview,management team,board of directors,scientific advisors,governance/compliance,product candidates,news and events,press releases,company news,company events,presentations,publications,media resources,investors,investor relations,quote
SERVER
Apache/2.4.12 (Ubuntu)
POWERED BY
PHP/5.5.9-1ubuntu4.11
CONTENT-TYPE
utf-8
GOOGLE PREVIEW

Investor Relations :: Relmada Therapeutics, Inc. (RLMDD) | ir.relmada.com Reviews

https://ir.relmada.com

REL-1017 (dextromethadone, d-Methadone). Cash position on March 31, 2015. Headcount as of December 31, 2014. Common stock outstanding at May 15, 2015. Aug 17, 2015. Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist. Sign Up for E-Mail Alerts. Be the first to receive breaking news. Mar 31, 2015. Officers & Directors. Slide" data-cycle-swipe="true" data-cycle-timeout= 0. Douglas J. Beck. Michael D. Becker. Dr Mangano has ...

INTERNAL PAGES

ir.relmada.com ir.relmada.com
1

Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark :: Relmada Therapeutics, Inc. (RLMD)

http://ir.relmada.com/press-releases/detail/92

Scientific and Business Advisors. REL-1017 (dextromethadone, d-Methadone). Enrollment in Relmada Therapeutics'. Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark. June 29, 2015. Company On Track to Report Top-Line Data in Second Half of 2015. About Relmada Therapeutics, Inc. Michael Becker, SVP of Finance and Corporate Development. Berry and Company Public Relations. SOURCE Relmada Therapeutics, Inc. Released June 29, 2015.

2

Management Team :: Relmada Therapeutics, Inc. (RLMD)

http://ir.relmada.com/management-team

Scientific and Business Advisors. REL-1017 (dextromethadone, d-Methadone). Sergio Traversa, PharmD, MBA ,. Richard M. Mangano, PhD ,. Dr Mangano holds a B.S degree in Chemistry from Iona College and a PhD degree in Biochemistry from Fordham University. Prior to joining the pharmaceutical industry, he was a research faculty member of the Maryland Psychiatric Research Institute at the University of Maryland School of Medicine. Michael D. Becker ,.

3

Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist :: Relmada Therapeutics, Inc. (RLMD)

http://ir.relmada.com/press-releases/detail/121/relmada-therapeutics-receives-health-canada-clearance-to

Scientific and Business Advisors. REL-1017 (dextromethadone, d-Methadone). Relmada Therapeutics Receives Health Canada. Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist. August 17, 2015. Aug 17, 2015. CEO of Relmada Therapeutics. "Assuming successful completion of the multiple ascending dose study, d-Methadone should enter Phase 2 proof of concept clinical development in the first half of 2016.". Alone The main classes...

4

Press Releases :: Relmada Therapeutics, Inc. (RLMD)

http://ir.relmada.com/press-releases

Scientific and Business Advisors. REL-1017 (dextromethadone, d-Methadone). Relmada Therapeutics to Present at the Sidoti and Company Fall 2016 Emerging Growth Convention. October 27, 2016. Relmada Therapeutics Announces Issuance of Key U.S. Patent Covering d-Methadone, an NMDA Receptor Antagonist, for the Treatment of Depression and Other Psychiatric Symptoms. October 19, 2016. Relmada Therapeutics to Present at the 15th Annual BIO Investor Forum. October 6, 2016. September 28, 2016. September 22, 2016.

5

Board of Directors :: Relmada Therapeutics, Inc. (RLMD)

http://ir.relmada.com/board-of-directors

Scientific and Business Advisors. REL-1017 (dextromethadone, d-Methadone). Sandesh Seth, MS, MBA ,. Charles J. Casamento, MBA ,. Paul Kelly, MBA ,. Maged Shenouda, R.Ph, MBA ,. Sergio Traversa, PharmD, MBA ,.

UPGRADE TO PREMIUM TO VIEW 1 MORE

TOTAL PAGES IN THIS WEBSITE

6

OTHER SITES

ir.refire-online.com ir.refire-online.com

home ~ REFIRE online ~ Real Estate Intelligence Report - Europe

Declaration of PropertyCollection: create() should be compatible with ItemCollection: create() in /home/www refire/www.production/contenido/classes/class.properties.php. Declaration of PropertyItem: setField() should be compatible with Item: setField($field, $value, $safe = true) in /home/www refire/www.production/contenido/classes/class.properties.php. Declaration of DBFSCollection: create() should be compatible with ItemCollection: create() in /home/www refire/www.production/contenido/classes/class...

ir.regenxbio.com ir.regenxbio.com

Investor Overview - Investors - REGENXBIO

160; 0.20. Data as of 01/12/17 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. REGENXBIO Provides Year-End 2016 Corporate Update. REGENXBIO and Voyager Therapeutics Announce Exercise of Options for Rights to NAV Vectors. ROCKVILLE, Md. and CAMBRIDGE, Mass., Nov. 29, 2016 (GLOBE NEWSWIRE) - REGENXBIO Inc. (Nasdaq:RGNX), a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based ...On track to d...

ir.regions.com ir.regions.com

Regions Financial Corporation - Investor Relations

Spectrum Card - Employee. Spectrum Card - Employer. 4:02 PM ET, 03/29/18. Regions is scheduled to release 1Q18 results on Friday April 20, 2018. Live teleconference and webcast beginning at 11am EST. Rarr; Learn More. Listen to the replay and read the transcript of Regions Executives present at the 2018 Credit Suisse Financial Services Conference. Rarr; Learn More. Website Terms of Use.

ir.regulusrx.com ir.regulusrx.com

Regulus Therapeutics Inc. - Investor Relations

Skip to primary content. Skip to secondary content. Road to the Clinic. Biology & Pharmacology. 4:00 PM ET on Aug 17, 2015. Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting. RNA therapeutics pipeline entering clinical development, an emerging. RNA biomarkers platform to support its therapeutic programs, and a rich intellectual property estate to retain its leadership in the. RNA field have enabled the formation ...

ir.rehabcare.com ir.rehabcare.com

Rehabcare : Overview

Founded in 1982, RehabCare is a leading provider of services across the post-acute continuum of care, operating programs and hospitals nationwide. RehabCare is a publicly traded company, listed on the NYSE under the symbol RHB, and is included in the Russell 2000 and Standard and Poor’s Small Cap 600 Indices. Could not find file ' aws.nasdaqomx.com irweb content3 IRXMLDATA 68 68419 Quotes.xml'. RehabCare Reports First Quarter 2011 Results. RehabCare To Announce First Quarter 2011 Results. Replication or ...

ir.relmada.com ir.relmada.com

Investor Relations :: Relmada Therapeutics, Inc. (RLMDD)

REL-1017 (dextromethadone, d-Methadone). Cash position on March 31, 2015. Headcount as of December 31, 2014. Common stock outstanding at May 15, 2015. Aug 17, 2015. Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist. Sign Up for E-Mail Alerts. Be the first to receive breaking news. Mar 31, 2015. Officers & Directors. Slide" data-cycle-swipe="true" data-cycle-timeout= 0. Douglas J. Beck. Michael D. Becker. Dr Mangano has ...

ir.remarkmedia.com ir.remarkmedia.com

Company Information | Remark Holdings

Skip to main navigation. Investor Relations - Horizontal. Remark Holdings (NASDAQ: MARK. Mar 29, 2018. Remark Holdings Reports Fourth Quarter and Full Year 2017 Results. Mar 23, 2018. Remark Holdings Moves Up Fourth Quarter and Full Year 2017 Earnings Call to Thursday, March 29, 2018 at 8:30 am ET. Mar 16, 2018. Remark Holdings Sets Fourth Quarter and Full Year 2017 Earnings Call for Thursday, March 29, 2018 at 4:30 pm ET. Mar 09, 2018. Mar 05, 2018. Feb 12, 2018. View all press releases.

ir.remyinc.com ir.remyinc.com

Remy - Investors Overview

Stock Quote and Chart. 160; 0.11. Data as of 08/17/15 4:00 pm ET. Minimum 20 minute delay. August 13, 2015. Remy Announces Early Termination Of Hart-Scott-Rodino Waiting Period For Pending Acquisition Of Remy By BorgWarner. August 03, 2015. Remy International, Inc. Announces Second Quarter 2015 Results. July 30, 2015. Remy International, Inc. Announces Declaration of Dividend on Common Stock; Cancels 2nd Quarter Earnings Conference Call. There are currently no events scheduled.

ir.renesola.com ir.renesola.com

Renesola - Investors - Investor Home

Stock Quote and Chart. Founded in 2005, and listed on the New York Stock Exchange in 2008, ReneSola (NYSE:SOL) is an international leading brand and technology provider of green energy products. Leveraging its global presence, expansive OEM and sales network, Renesola is well positioned to provide its highest quality green energy products and on-time services for EPC, installers, and green energy projects around the world. For more information, please visit www.renesola.com. Tel: 86-21-62809180 ext 105.

ir.rennovahealth.com ir.rennovahealth.com

Investor Relations :: Rennova Health, Inc. (RNVA)

Rennova Health Provides Outlook for 2017. January 5, 2017. Rennova Health Provides Outlook for 2017. Jan 5, 2017. Ended Sep 30, 2016. Sign Up for Email Alerts. Be the first to receive breaking news. Jersey City, NJ 07310. 10320 N 56th Street. Tampa, FL 33617.

ir.renren-inc.com ir.renren-inc.com

Renren - INVESTOR RELATIONS - Overview

Started from university campuses in 2005, we now possess a nation-wide penetration with users across all demographics, particularly college students and young white-collar professionals. Our social networking platform serves as the foundation of our business and we aim to build a mobile-centric eco-system that embodies our user needs. As a leader in mobile social networking, we are dedicated in continuing to transform ourselves into a full-fledged mobile technology Company. 160; 0.02. This calendar conta...